A5071430304- Systemic Lupus Erythematosus Research
- Monoclonal and Polyclonal Antibodies Research
- Atherosclerosis and Cardiovascular Diseases
- T-cell and B-cell Immunology
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Systemic Sclerosis and Related Diseases
- Rheumatoid Arthritis Research and Therapies
- Lymphoma Diagnosis and Treatment
- Cytokine Signaling Pathways and Interactions
- Salivary Gland Disorders and Functions
- Peripheral Neuropathies and Disorders
- Renal Diseases and Glomerulopathies
- Autoimmune and Inflammatory Disorders Research
- Chronic Lymphocytic Leukemia Research
- Liver Diseases and Immunity
- Musculoskeletal Disorders and Rehabilitation
- Medical and Biological Sciences
- Diabetes and associated disorders
- Musculoskeletal pain and rehabilitation
- Complement system in diseases
- Osteoarthritis Treatment and Mechanisms
- Immune Cell Function and Interaction
- Reproductive System and Pregnancy
- Pharmacological Effects of Natural Compounds
- Multiple Sclerosis Research Studies
Cedars-Sinai Medical Center
2016-2025
University of California, Los Angeles
2015-2024
Naval Medical Research Command
2024
University of West Florida
2023
University of California System
2022
Center for Rheumatology
2019-2021
Queen Elizabeth II Health Sciences Centre
2019
Dalhousie University
2019
Dana-Farber Cancer Institute
2016
Rheumatology Consultants
2016
The Systemic Lupus International Collaborating Clinics (SLICC) group revised and validated the American College of Rheumatology (ACR) systemic lupus erythematosus (SLE) classification criteria in order to improve clinical relevance, meet stringent methodology requirements, incorporate new knowledge regarding immunology SLE.The were derived from a set 702 expert-rated patient scenarios. Recursive partitioning was used derive an initial rule that simplified refined based on SLICC physician...
To develop new classification criteria for systemic lupus erythematosus (SLE) jointly supported by the European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR).This international initiative had four phases. 1) Evaluation antinuclear antibody (ANA) as an entry criterion through systematic review meta-regression literature generation Delphi exercise, early patient cohort, a survey. 2) Criteria reduction nominal group technique exercises. 3) definition weighting...
To assess the efficacy/safety of B lymphocyte stimulator inhibitor belimumab plus standard therapy compared with placebo in active systemic lupus erythematosus (SLE).In a phase III, multicenter, randomized, placebo-controlled trial, 819 antinuclear antibody-positive or anti-double-stranded DNA-positive SLE patients scores ≥6 on Safety Estrogens Lupus Erythematosus National Assessment (SELENA) version Disease Activity Index (SLEDAI) were randomized 1:1:1 ratio to receive 1 mg/kg belimumab, 10...
In the United States, approximately 35% of adults with Systemic Lupus Erythematosus (SLE) have clinical evidence nephritis at time diagnosis; an estimated total 50–60% developing during first 10 years disease [1–4]. The prevalence is significantly higher in African Americans and Hispanics than Caucasians, men women. Renal damage more likely to develop non-Caucasian groups [2–4]. Overall survival patients SLE 95% 5 after diagnosis 92% [5, 6]. presence lupus reduces survival, 88% years, even...
Abstract Objective B cells are likely to contribute the pathogenesis of systemic lupus erythematosus (SLE), and rituximab induces depletion cells. The Exploratory Phase II/III SLE Evaluation Rituximab (EXPLORER) trial tested efficacy safety versus placebo in patients with moderately‐to‐severely active extrarenal SLE. Methods Patients entered ≥1 British Isles Lupus Assessment Group (BILAG) A score or ≥2 BILAG scores despite background immunosuppressant therapy, which was continued during...
Since anecdotal series and small, prospective, controlled trials suggest that mycophenolate mofetil may be effective for treating lupus nephritis, larger are desirable.We conducted a 24-week randomized, open-label, noninferiority trial comparing oral (initial dose, 1000 mg per day, increased to 3000 day) with monthly intravenous cyclophosphamide (0.5 g square meter of body-surface area, 1.0 meter) as induction therapy active nephritis. A change the alternative regimen was allowed at 12 weeks...
Letters and Corrections1 September 1988Dubois' Lupus ErythematosusDaniel J. Wallace, MDDaniel MDAuthor, Article, Disclosure Informationhttps://doi.org/10.7326/0003-4819-109-5-436_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editor:Regarding Dr. Mandell's letter (1) in June issue, I also am quite dismayed that our textbook,Dubois' Erythematosus(3rd edition), was not included A Library for Internists...
Abstract Objective To investigate the efficacy and tolerability of infliximab therapy for articular dermatologic manifestations active psoriatic arthritis (PsA). Methods One hundred four patients with PsA in whom prior at least 1 disease‐modifying antirheumatic drug (DMARD) had failed were recruited into this investigator‐initiated, multicenter, randomized, double‐blind, placebo‐controlled clinical trial. During initial blinded portion study, received infusions (5 mg/kg) or placebo weeks 0,...
Abstract Objective CD40–CD40 ligand (CD40L) interactions play a significant role in the production of autoantibodies and tissue injury lupus nephritis. We performed an open‐label, multiple‐dose study to evaluate safety, efficacy, pharmacokinetics BG9588, humanized anti‐CD40L antibody, patients with proliferative The primary outcome measure was 50% reduction proteinuria without worsening renal function. Methods Twenty‐eight active nephritis were scheduled receive 20 mg/kg BG9588 at biweekly...
Abstract Objective To assess the safety, tolerability, biologic activity, and efficacy of belimumab in combination with standard care therapy (SOC) patients active systemic lupus erythematosus (SLE). Methods Patients a Safety Estrogens Lupus Erythematosus: National Assessment (SELENA) version Systemic Erythematosus Disease Activity Index (SLEDAI) score ≥4 (n = 449) were randomly assigned to (1, 4, or 10 mg/kg) placebo 52‐week study. Coprimary end points percent change SELENA–SLEDAI at week...
Abstract Elevated spontaneous IgG production is characteristic of SLE. To identify the factors that support it, IL-6, a cytokine with an important role in differentiation IgG-secreting cells, was studied SLE patients. Higher than normal levels IL-6 were found, by B9 assay, sera 63 70 patients (p less 0.05). detected 36 37 active higher titers = 0.009) those for inactive (n 33), which 0.05) healthy controls 15). mRNA freshly isolated PBMC 11 but not PBMC, whereas IL-1 only disease. activity...
Objective. To determine nephritis outcomes in a prospective multi-ethnic/racial SLE inception cohort. Methods. Patients the Systemic Lupus International Collaborating Clinics cohort (≤15 months of diagnosis) were assessed annually for estimated glomerular filtration rate (eGFR), proteinuria and end-stage renal disease (ESRD). Health-related quality life was measured by Short Form (36 questions) health survey questionnaire (SF-36) subscales, mental physical component summary scores. Results....
<h3>Background and aims</h3> We studied damage accrual factors determining development progression of in an international cohort systemic lupus erythematosus (SLE) patients. <h3>Methods</h3> The Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort recruited patients within 15 months developing four or more 1997 American College Rheumatology (ACR) criteria for SLE; the SLICC/ACR index (SDI) was measured annually. assessed relative rates transition using maximum...
Abstract Objective To describe a new systemic lupus erythematosus (SLE) responder index (SRI) based on belimumab phase II SLE trial and demonstrate its potential utility in clinical trials. Methods Data from randomized, double‐blind, placebo‐controlled study 449 patients of 3 doses (1, 4, 10 mg/kg) or placebo plus standard care therapy (SOC) over 56‐week period were analyzed. The Safety Estrogens Lupus Erythematosus: National Assessment (SELENA) version the Systemic Erythematosus Disease...
Abstract Objective Women with systemic lupus erythematosus (SLE) have a 7–50‐fold increased risk of coronary artery disease (CAD). In the general population, oxidized low‐density lipoprotein (ox‐LDL) increases for CAD. Normal high‐density lipoproteins (HDLs) protect LDL from oxidation; proinflammatory HDLs do not. This study was undertaken to determine whether patients SLE, who chronic inflammation that causes oxidative damage, more HDL and higher levels ox‐LDL, thus predisposing them...
Systemic lupus erythematosus (SLE) is an autoimmune disease with marked gender and ethnic disparities. We report a large transancestral association study of SLE using Immunochip genotype data from 27,574 individuals European (EA), African (AA) Hispanic Amerindian (HA) ancestry. identify 58 distinct non-HLA regions in EA, 9 AA 16 HA (∼50% these have multiple independent associations); include 24 novel (P<5 × 10-8), refined signals established regions, extended associations to additional...
Abstract Objective To evaluate abatacept therapy in patients with non–life‐threatening systemic lupus erythematosus (SLE) and polyarthritis, discoid lesions, or pleuritis and/or pericarditis. Methods In a 12‐month, multicenter, exploratory, phase IIb randomized, double‐blind, placebo‐controlled trial, SLE pericarditis were randomized at ratio of 2:1 to receive (∼10 mg/kg body weight) placebo. Prednisone (30 mg/day equivalent) was given for 1 month, then the dosage tapered. The primary end...
To identify a suitable dosing regimen of the CD22-targeted monoclonal antibody epratuzumab in adults with moderately to severely active systemic lupus erythematosus (SLE).A phase IIb, multicentre, randomised controlled study (NCT00624351) was conducted 227 patients (37-39 per arm) receiving either: placebo, 200 mg cumulative dose (cd) (100 every other week (EOW)), 800 cd (400 EOW), 2400 (600 weekly), (1200 or 3600 (1800 EOW). The primary endpoint (not powered for significance) 12 responder...
Objectives To determine the frequency, accrual, attribution and outcome of neuropsychiatric (NP) events impact on quality life over 3 years in a large inception cohort patients with systemic lupus erythematosus (SLE). Methods The study was conducted by Systemic Lupus International Collaborating Clinics. Patients were enrolled within 15 months SLE diagnosis. NP identified using American College Rheumatology case definitions, decision rules derived to proportion disease attributable SLE....
To evaluate the safety and tolerability of multiple intravenous (IV) doses sifalimumab in adults with moderate-to-severe systemic lupus erythematosus (SLE).In this multicenter, double-blind, placebo-controlled, sequential dose-escalation study, patients were randomized 3:1 to receive IV (0.3, 1.0, 3.0, or 10.0 mg/kg) placebo every 2 weeks week 26, then followed up for 24 weeks. Safety assessment included recording treatment-emergent adverse events (AEs) serious AEs. Pharmacokinetics,...
<h3>Objectives</h3> Evaluate efficacy and safety of tabalumab, a human IgG4 monoclonal antibody that binds neutralises membrane soluble B-cell activating factor (BAFF) versus placebo plus standard care (SoC) in patients with systemic lupus erythematosus (SLE). <h3>Methods</h3> This phase III, 52-week study randomised 1164 moderate-to-severe SLE (Safety Estrogens Lupus Erythematosus National Assessment—SLE Disease Activity Index ≥6 at baseline). Patients received SoC subcutaneous injections...
Objective Epratuzumab, a monoclonal antibody that targets CD22, modulates B cell signaling without substantial reductions in the number of cells. The aim this study was to report results 2 phase III multicenter randomized, double‐blind, placebo‐controlled trials, EMBODY 1 and assessing efficacy safety epratuzumab patients with moderately severely active systemic lupus erythematosus (SLE). Methods Patients met ≥4 American College Rheumatology revised classification criteria for SLE, were...